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Background: Allergic reactions to one or more beta-lactam antibiotic can pose a management problem in patients with cystic fibrosis (CF),
and may limit antibiotic choice.
Method: The aim of this study was to assess the prevalence of allergy to anti-pseudomonal beta-lactam antibiotics in an adult CF centre and
to assess variables, which may contribute to the development of allergic reactions. A questionnaire-based interview and a review of medical
records were performed.
Results: Of the 150 patients, 54 (36%) had allergic reactions to one or more beta-lactam antibiotics and 20 (19%) had allergic reactions to
multiple beta-lactam antibiotics. The proportion of patients allergic to specific beta-lactam antibiotics varied from 10% to 26%. Rates of
reactions were highest for penicillins and cephalosporins, intermediate for carbepenems and lowest for aztreonam. Of all reactions, 40%
occurred within 24 h of the commencement of an individual antibiotic course. Patients with one or more beta-lactam allergic reactions had
received greater cumulative exposure ( pb0.0001), were older ( p=0.016) and had lower lung function ( p=0.037) than patients without a
history of beta-lactam allergy. Cystic Fibrosis transmembrane regulator (CFTR) status, gender, peripheral blood eosinophil count and total
IgE concentrations were not different in patients with allergic reactions.
Conclusions: This study demonstrates that the prevalence of allergic reactions to beta-lactam antibiotics is high in adults with CF. Increasing
age; cumulative exposure and decreasing FEV1 were associated with the development of allergy.
© 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Allergy; Antibiotics; Beta-lactam; Cystic fibrosis; Desensitization1. Introduction
Cystic fibrosis (CF) is the most common lethal recessively
inherited disease of Caucasians. Most of the morbidity and
mortality is related to chronic suppurative lung disease [1]. The
prevalence of Pseudomonas aeruginosa (P. aeruginosa)
increases with age and approaches 80% in adults with CF
[2]. The current recommended treatment for pulmonary
exacerbations of P. aeruginosa includes the combination of
intravenous beta-lactam antibiotic and an aminoglycoside for⁎ Corresponding author. Adult Cystic Fibrosis Centre, The Prince Charles
Hospital, Rode Road, Chermside, Brisbane, 4032, Australia. Tel.: +61 7
33508770; fax: +61 7 32125630.
E-mail address: scott_bell@health.qld.gov.au (S.C. Bell).
1569-1993/$ - see front matter © 2006 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2006.11.00110 to 21 days [3,4]. Anti-pseudomonal beta-lactam antibiotics
available in Australia are licensed only for intravenous
use. These antibiotics from four classes include penicillins
(ticarcillin and piperacillin), cephalosporins (cefpirome,
cefepime and ceftazidime), carbapenems (imipenem and
meropenem) and a monobactam (aztreonam). Since the mid-
1990's, ticarcillin has only been available in combination with
clavulanic acid (Timentin®). Piperacillin is available in two
preparations, piperacillin alone (Pipril®) and in combination
with tazobactam (Tazosin®). Imipenem has only been
available in combination with cilastatin (Primaxin®).
Beta-lactam antibiotic allergy has been variably reported
from less than one percent up to eight percent of patients in
the general population [5]. Several reports including three
cohort studies, describe a higher prevalence of allergiced by Elsevier B.V. All rights reserved.
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(≥29%) [6–13]. The highest reported prevalence was
reported in Danish patients where over 60% of patients had
an allergic reaction to one or more beta-lactam antibiotics
[11]. These reactions manifest with a variety of symptoms
including anaphylaxis, pruritis, rash and drug fever.
Several components of the immune system may be in-
volved including B- and T-lymphocytes, mast cells and
basophils in allergic reactions. Complement activation and
antibody response may be involved especially IgG, IgE and
IgM [14]. A recent review has highlighted the lack of
published information regarding antibiotic allergy in patients
with CF, in particular the role of specific CFTR mutations,
cumulative exposure, and previous allergy to related anti-
biotics in the development of allergic reactions [15].
The primary aim of this study was to determine the
prevalence of allergy to beta-lactam antibiotics in adults with
CF in the current era. The study also assessed patient recall
of allergy episodes and variables which may have contrib-
uted to the development of antibiotic allergy. The hypothesis
tested was that allergy to beta-lactam antibiotics results from
cumulative exposure in CF patients.
2. Methods
2.1. Setting and patient selection
The Prince Charles Hospital (TPCH) provides care for
200 patients with CF with some patients receiving shared
care with regional hospitals in Queensland (3.5 million km2),
Northern NSW and Northern Territory. Adults attending the
Adult CF Centre in April 2004 including post lung transplant
patients were studied. Some patients received intravenous
therapy solely at TPCH and Royal Children's Hospital
(RCH), and some had previously been managed elsewhere.
2.2. Study design
The retrospective study comprised of two components:
1) a structured questionnaire-based telephone interview; and
2) data collection from the medical record. The interview
collected demographic information and data about expo-
sure to beta-lactam antibiotics, hospitals attended, history of
home intravenous therapy, and beta-lactam related allergic
reactions. Further information was sought from patients with
a previous allergic reaction including timing, symptoms and
location of reactions, previous exposure and treatment of
reactions.
A review of medical records at TPCH for the 150 patients
was performed using a structured approach to collect the
following data: antibiotic exposure, documentation, symp-
toms and timing of reactions and clinical information,
including IgE concentrations, peripheral blood eosinophil
count, and FEV1% predicted. The most recent results
available within 12 months of April 2004 were recorded.
In most cases, these were collected during clinical stability atan outpatients review (annual assessment) except when
logistical issues precluded this and then blood was collected
at the end of treatment of an infective exacerbation. Skin
testing was infrequently performed and was not analysed
further. The records of patients who had attended RCH as
children were also examined using the same structured
approach. In view of the size of the catchment area of the
centre, some patients had received some care in hospitals
other than TPCH or RCH. Total cumulative exposure was
calculated for patients who attended only TPCH and RCH
and data was collected up to the time of lung transplantation.
All of the data from the medical record review was collected
using a consistent structured approach by JAB at TPCH and
RCH. Reactions that occurred at hospitals other than TPCH
or RCH could not be verified in medical records. When the
patient could provide clear details of the time and place of a
reaction and the drug involved and symptoms were typical of
an allergic reaction, data was documented as for verified
reactions. Reactions were classified as life threatening or
non-life threatening.
The classification of allergic reactions according to time
interval between last dose administration and their onset was
proposed by Levine: immediate reactions that occur within
1 h, accelerated reactions that occur from one to 24 h and
delayed reactions from 24 to 72 h or more [16]. Non-
immediate reactions are those occurring more than 1 h after
drug administration. A simplified classification has been
adopted by the European Network of Drug Allergy (http://
www.eaaci.net) in immediate and non-immediate reactions
[17]. Immediate reactions occur within the first hour after
drug administration and non-immediate reactions are those
occurring after 1 h of drug administration. However, docu-
mentation in the medical record did not always include the
exact timing of many reactions with respect to administra-
tion, making such classification difficult. This necessitated
the adoption of a modified classification system for the
purposes of this study. “Early” reactions were classified as
occurring b24 h after the commencement of a specific course
and “delayed” reactions after 24 h.
2.3. Statistical analysis
Descriptive statistical test analysis was performed using
the Number Cruncher Statistical Software (NCSS®). Patients
were divided into two groups (no allergic reactions or ≥ one
previous reaction). Statistical tests included chi-square (or
Fisher's exact test (where numbers ≤6)), t-tests and Mann-
Whitney U tests where appropriate. A p value ofb0.05 was
considered statistically significant. The logistic regression
analysis was chosen to describe the relationship between
outcome (allergy or no allergy) and the variables collected
during the study. The model was built using NONMEM
version 5 and the G77 Fortran compiler. Variables were
added manually to the model in a forward sequential manner.
Parameters that allowed for interaction between the variables
were also added until the full model was obtained. The
Fig. 1. Patient recruitment at the Adult CF Centre, TPCH.
Table 1
Allergy to combinations of beta-lactam antibiotics
Antibiotic
combinations
Patients
allergic to both
antibiotics (#)
Patients
exposed to both
antibiotics (#)
Patients exposed to both
with allergic reactions to
both antibiotics (%)
Ticarcillin 11 120 9.2
Ceftazidime
Ticarcillin 6 71 8.5
Meropenem
Ticarcillin 2 41 4.9
Imipenem
Ceftazidime 9 75 12.0
Meropenem
Ceftazidime 4 51 7.8
Aztreonam
Meropenem 4 41 9.8
Aztreonam
Imipenem 2 28 7.1
Aztreonam
Ticarcillin 3 51 5.8
Aztreonam
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peting models with a change in N3.84 units (corresponding
to a pb0.05 according to a chi-squared distribution) con-
sidered significant.
The study was approved by TPCH and RCH Human
Research and Ethics committees and the University of
Queensland Ethics committee. All patients provided written
consent before accessing their patient information.
3. Results
The available cystic fibrosis patient population in the
Queensland area was 200 patients. One hundred and fifty
(150) patients participated in the study (Fig. 1) (April–
November 2004). The median age of the study group was
26 years (range 17–57) and 43% were female. Nineteen
patients (13%) had received a lung transplant. Total lifetime
cumulative antibiotic exposure was available for 73 of 150
(49%) patients.
3.1. Prevalence of allergic reactions
A total of 54 of the 150 (36%) patients experienced at
least one allergic reaction to an anti-pseudomonal beta-
lactam antibiotic. No patients experienced an allergic
reaction to intravenously administered aminoglycosides.
Subsequent administration without incident (allergic phe-
nomenon) of aminogylcosides (usually tobramycin) with a
different beta-lactam antibiotic excluded an initial amino-
glycoside reaction in all cases. The 54 patients had a total of
93 allergic reactions (0.6 reactions per patient in the overall
population and 1.7 reactions per patient with allergy). Of the
patients with beta-lactam allergy, 63% (n=34) had allergic
reaction to one beta-lactam drug class, 20% (n=11) to two
beta-lactam classes, 11% (n=6) to three beta-lactam classes
and 6% (n=3) to all four beta-lactam classes. Most patients
(14 of 20) with two or more allergies were allergic to both
penicillins and cephalosporins. However, six patients were
allergic to combinations other than penicillins and cepha-losporins. The rates of cross-sensitivity to different combina-
tions of antibiotics in patients exposed are summarised in
Table 1. The percentage of patients with allergies to the
differing combinations ranged from 4.9% to 12.0%. The
majority of reactions (72%) occurred while patients were
under the care of TPCH, with 11 (of 93) having reactions
while receiving home intravenous therapy. Only 13 of 93
(14%) reactions occurred in patients less than 18 years.
For the patients who had data on cumulative exposure
(n=73), the patients received a total of 1321 courses or a
mean (±SD) number of courses per patient of 18.1±15.4.
This equates to a total of 14,349 days of therapy or a mean
(±SD) number of days per patient of 196±139 days. Of
these, 42 of the 1321 (3.2%) courses were complicated by
allergic reaction (or one reaction every 342 treatment days).
Details of patients exposed and specifics of allergy profiles
are given in Table 2. Ticarcillin and ceftazidime are currently
first line anti-pseudomonal beta-lactams in our centre and
these drugs have high rates of allergy.
3.2. Profile of allergic phenomenon
Of the 93 reactions, 37 (40%) were “early” reactions and
56 (60%) were “delayed”. Two reactions were considered
life-threatening (anaphylaxis) and required adrenaline (ticar-
cillin and ceftazidime). Almost half of the reactions that
manifested after 24 h occurred more than seven days into a
course. Aztreonam was the only antibiotic which did not
have any acute reactions recorded and there were no delayed
reactions found with piperacillin.
A variety of allergy related symptoms was experienced by
the 54 patients (Fig. 2). Pruritis and rash were most common
followed by a wide range of other symptoms. Dyspnoea,
cutaneous tingling and angioedema manifested more com-
monly in reactions occurring within 24 h and fever and
flushing in reactions occurring after 24 h from commencement
Table 2
Allergy profiles for specific beta-lactam antibiotics
Class Antibiotic Patients exposed
(#)
Patients exposed /population
(%)
Allergic patients
(#)
Allergic patients /patients exposed
(%)
Time of allergy
(course)⁎
Penicillins Ticarcillin 132 88 29 22 7 (4,10)
Piperacillin 23 15 6 26 3
Cephalosporins Ceftazidime 137 91 31 23 3 (2,18)
Cefepime 12 8 3 25 0
Cefpirome 5 3 0 0 0
Carbapenems Imipenem 40 26 6 15 2
Meropenem 78 52 13 17 3 (2,3)
Monobactams Aztreonam 51 34 5 10 8
⁎Number of courses of specific antibiotics given prior to development of allergic reaction based on 73 patients where cumulative exposure was available.
Reported results are medians (25th, 75th percentiles). If patients numbers ≤6, median is reported.
Table 3
Clinical features in relation to allergy status
Variable No allergies
(n=96)
One or more
allergies (n=54)
p value
Age of patients
[n=150]⁎
24.5 (19, 30)
[n=96]
28 (23,33)
[n=54]
p=0.016#
Age ≥25 years
[n=150]$
50%
[n=96]
70%
[n=54]
p=0.015¶
Cumulative courses 6 (2, 20) 29 (17, 47) p=0.00005#
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haemorrhagic cystitis (eight episodes), hepatitis (two epi-
sodes) and isolated reports of shakiness, loss of peripheral
vision, anxiety and dizziness. Each episode of haemorrhagic
cystitis was related to ticarcillin.
3.3. Patient knowledge and documentation in medical
record
Forty-five of 54 (83%) patients with one or more allergy
were able to accurately recall all reactions that were sub-
sequently documented in the medical record. Of the total
cohort, three patients (2%) experienced an allergic reaction,
that was documented and verified in the medical record, but
were unable to recall it. Eleven patients (7.3%) reported
allergic episodes, which were unable to be substantiated in
the medical record, despite the record being available and
thoroughly assessed. All of these patients were re-exposed
subsequently to the “reported” antibiotic without incident and
the “reported” reaction was discounted.
Accurate details of prior antibiotic allergy were docu-
mented in the current medical record (including inpatient and
outpatient) in 86% of patients. Only 50% had symptom
details of allergy and 20% had a date documented on the
front of the latest volume of the record.Fig. 2. Symptoms of allergy in early and delayed reactions⁎. ⁎Multiple
symptoms may have manifest for individual reactions.3.4. Risk factors for allergic reactions
The age of the patients was significantly greater in patients
with a history of allergic reactions than patients without an
allergic history ( pb0.05) (Table 3). The current FEV1%
predicted was also significantly lower in patients with a
history of beta-lactam allergy than those without such a
history ( pb0.05). Gender, CFTR status, IgE concentration
and peripheral blood eosinophil count were not different in
allergic patients. A higher proportion of patients over
25 years had allergies compared with younger patients
(Table 3). Patients with allergy were exposed to significantly
more courses of antibiotics than those without allergies
( p=0.00005). A higher proportion of patients with lifetime
exposure N20 courses had allergies to at least one antibiotic[n=73]$ [n=49] [n=24]
N20 courses of
antibiotics [n=73]⁎
29%
[n=49]
63%
[n=24]
p=0.019¶
Gender (F/M)
[n=150]$
40% / 60%
[n=96]
50% / 50%
[n=54]
NS¶
CFTR mutations
[n=126]$
[n=74] [n=52] NS¶
Δ F508/Δ F508 47% 58%
Δ F508/other 39% 31%
Other/other 14% 11%
FEV1 % predicted
[n=150]⁎
59 (40, 79)
[n=96]
50 (33, 67)
[n=54]
p=0.037#
IgE concentration
μg/L[n=122]⁎
132 (51, 456)
[n=74]
126 (35, 215)
[n=48]
NS#
Eosinophil count
X109/L [n=149]⁎
0.18 (0.01, 0.33)
[n=95]
0.21 (0.11, 0.34)
[n=54]
NS#
$Categorial data presented as percentages.
⁎Continuous data expressed as median (25th–75th percentile).
#Wilcoxon signed rank test, ¶chi-square test.
NS — Not significant.
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higher proportion of those with total exposure N20 courses
had allergy to two or more antibiotics (71%) than those with
less than 2 allergies (27%) (data not shown). The only
statistically significant univariate logistic regression models
that could be supported by the allergy data were cumulative
exposure (Δ likelihood=6.138) and FEV1% (Δ likeli-
hood=5.031). The final logit was described by −0.797+
0.483× (cumulative exposure / 20) and 0.358+−1.65×
(FEV1%/100). Joining these two variables using interaction
model (addition or multiplicative) did not significantly
improve the cumulative exposure model, i.e. Δ likelihood
b3.84 ( pN0.05).
4. Discussion
Studies of antibiotic allergy in patients with CF are
urgently required as evidenced by the imbalance between
three review articles [8,15,18] and three cohort studies of
allergy in patients with CF [9–11]. A recent review high-
lighted the need for studies of determinants of allergy in CF
patients [15]. The prevalence of allergy to intravenous anti-
pseudomonal beta-lactam antibiotics in this study was 36%
in adults with CF comparable with two other studies (29%
and 33%) [9,10] but lower than one study (61%) [11]. This
difference was evident despite increased age of patients in
the current study [11]. The increased prevalence of allergic
reactions reported by Koch et al. may relate to increased
cumulative exposure in patients who are routinely admitted
for parenteral therapy. Notably the single study which in-
volved only paediatric patients reported similar rates of beta-
lactam allergy as seen in the current report of adult patients
[10].
The greater usage of the immunogenic, piperacillin,
reported in the earlier studies may have also contributed to
the prevalence of allergy. The percentage of the patient group
exposed to piperacillin was highest in Koch's study (95%)
[11] and lower in Pleasants, Wills [9,10] and the current
study (34%, 25% and 15% respectively) [9–11]. Previously,
piperacillin tended to be associated with a higher allergy
risk (36% to 51%) in contrast with the current study (26%),
highlighting potential differences in the modern era of
antibiotic prescribing compared with earlier studies.
The previous studies in CF patients have consistently
reported the prevalence of allergic reactions to penicillins to
be higher than to cephalosporins [9–11]. Our study reports
similar rates of allergic reactions for these two drug classes.
This may result from the reduction in piperacillin adminis-
tration; the increasing use of other beta-lactams and in-
creased lifetime exposure to both classes with increased
survival. In all studies, including our study, the prevalence of
reactions to carbapenems and monobactams is less than other
antibiotic classes [9–11]. It is unclear if this relates to these
agents being less immunogenic or whether total exposure to
these agents is less as they are generally second line agents
and reserved for management of advanced lung disease.Almost 30% of reactions to ticarcillin manifested as
haemorrhagic cystitis which has features of an immunolog-
ical reaction involving the IgG and IgM [19,20].
Thirty-seven percent of patients with beta-lactam allergy
reacted to multiple antibiotics. This may result from cross-
sensitivity to related compounds (i.e. IgE antibodies to a
common chemical component) or result from separate
immune response to unrelated molecules. As ceftazidime
and aztreonam share common side chain structures, cross
sensitivity has been suggested to be a common clinical
problem [21]. However, only 7.8% of patients exposed to
both antibiotics were allergic to aztreonam and ceftazidime.
Rates of allergy to combinations of penicillins and car-
bapenems (4.9% and 8.5%) were no higher than any other
combinations (5.8% to 12.0%), as has been recently
suggested in the literature [22,23]. Aztreonam was success-
fully administered to many patients with other beta-lactam
allergies as previously reported [11,24–26]. Further study of
the mechanisms of allergic reactions is required to improve
understanding of cross-sensitivity. A higher proportion of
early reactions were found in the current study compared
with previous studies. Koch et al. reported that 28% of all
reactions were immediate (definition not provided) [11].
Forty percent of reactions in the current study occurred
within 24 h of initial dose of an antibiotic course. The high
rate of late reactions with piperacillin reported by Koch et al.
may contribute to this difference.
This study has demonstrated that knowledge of the timing
and features of a reaction do not necessarily provide in-
formation about the mechanism of the allergy (Fig. 3). Many
later reactions occurring during the delayed periods had
similar features to early reactions, making it difficult to
distinguish IgE from non-IgE mediated reactions. This
distinction is important as only IgE mediated reactions are
thought to be suitable for desensitization procedures [24].
4.1. Patient knowledge
We are not aware of any studies reporting the patient
recall of antibiotic-induced allergy in CF. This study
demonstrated that patients with CF were generally reliable
sources of information about their allergy history. Reassur-
ingly the false negative reporting of allergy was very low.
The importance of accurate documentation in the medical
record of details of allergic reactions is crucial to reduce the
risk of future adverse events [15].
4.2. Predictors of allergic phenomenon
In the current study, increasing age, cumulative exposure
and decreasing FEV1% predicted were correlated with the
presence of at least one beta-lactam allergy. Cumulative
exposure and FEV1% predicted but not age was predictive of
beta-lactam allergy by univariant analysis. Of note the
addition of FEV1% predicted to cumulative exposure did not
improve the prediction model. In a review of the topic, Moss
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with CF [8]. However, age may merely be a marker of
cumulative exposure rather than an independent variable
[17,20]. The lower FEV1 in those patients with allergy is
expected as lung function decreases with increasing age and
results in increasing antibiotic exposure.
The total courses of antibiotics patients were exposed to
were significantly higher in patients with at least one allergy
compared to those without allergy. A higher proportion of
patients with a cumulative exposure greater than 20 courses
had experienced at least one allergy compared with those
without allergy. Wills et al. also reported an association
between the number of reactions and the number of
antibiotic courses [10]. Six of seven patients who received
20 or more intravenous courses had at least three antibiotic
reactions which were more than those with less than 20
courses (one of 23 patients). This is supported by the high
prevalence of allergy in patients with high antibiotic
exposure in the Danish patients [11].
Our data suggest that nonspecific markers of atopy
including blood eosinophil count and IgE concentrations are
not related to the development of allergic reactions. Similarly,
gender and specific CFTR mutations are not related to the
occurrence of allergy. However, the factors which contribute to
the development of allergic reactions to beta-lactam antibiotics
are likely to be complex. Interestingly, 14 of 49 (29%) of
patients who had not developed any allergic reactions had a
cumulative exposure of greater than 20 courses (nine over 30
courses and one patient over 80 courses). This suggests that
there must be additional factors which influence the risk of
an allergic reaction to beta-lactams.
4.3. Limitations of the study
There are a number of limitations when considering our
findings. Thirty-one of the population (16%) declined in-
volvement or were not contactable. Patients with milder
disease who are less frequently reviewed at the centre may
have not participated, which could lead to an over-estimation
of the allergy rate. As this was a retrospective study, details
of the timing and symptoms of reactions were not always
precise and analysis was based on the number of patients
where data were available. A prospective birth cohort study
would be required to circumvent this limitation.
Access to all medical records for all patients to calculate
total cumulative lifetime exposure was impractical in this
study. Despite this limitation the cohort whose cumulative
exposure was available had similar clinical characteristics to
the whole cohort. The reliance on patient recall of antibiotic
exposure and allergy where data could not be verified in the
medical record (i.e. those patients managed at hospitals in
addition to RCH and TPCH) may have led to inaccuracies in
classification of individual patients (nature and timing of
event), particularly when exposure or allergy occurred many
years previously. The patient's self-reported antibiotic expo-
sure and allergies were also used to guide the process findingrelevant information in the medical records. It is possible that
some data may have been missed despite efforts to collect
complete information. In the future the development of
complete electronic medical records may allow for more
accurate recording of adverse events in patients with CF.
Notably, the symptoms of drug allergy were protean and
in some cases were non-specific (e.g. anxiety, flushing,
pain). These symptoms may present allergic phenomenon,
however, may be a result of other clinical events. Cautious
re-exposure of beta-lactam in this situation may better define
whether a true allergy has occurred and under close medical
supervision may be appropriate in some cases.
In conclusion, allergic reactions to anti-pseudomonal
beta-lactam antibiotics are common in patients with CF.
Penicillin and cephalosporins appear to have a similar risk of
allergy and many patients are allergic to multiple antibiotics.
High cumulative exposure and lower FEV1 were associated
with the development of beta-lactam allergy and the in-
creasing survival of patients with CF and aggressive pro-
tocols for treatment of P. aeruginosa are likely to result in
many patients having limited antibiotic choice due to allergic
reactions.
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